SFJ PROPEL3
19 Apr 2022
Trial Summary
A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined with Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma with PD-L1 Expressing Tumors (PROPEL-36)
Acronym:
PROPEL-36
ACTRN/NCT /ethics:
NCT04969861
Scientific title:
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Sponsor / Cooperative group:
Nektar Therapeutics
Trial & Patient Characteristics
| Cancer Type | Head and Neck |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II; Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2022-03-09 |
| Anticipated End Date | 2026-05-01 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | Dr Sarwan Bishnoi |
| Recruitment Status | Recruiting |